Al-Jazeerah: Cross-Cultural Understanding
News, August 2020
773,065 Deaths and 21,825,601 Corona Virus Infections, Mostly in the US, Brazil, Mexico, India, UK, Italy, France, Spain, and Peru
August 16, 2020
As of August 17, 2020, 03:48 GMT
World: 21,825,601 infection cases, and 773,065 deaths.
A list of countries with the highest Coronavirus (Covid-19) deaths:
1 USA 5,566,632 infection cases, and 173,128 deaths.
3 Mexico 522,162 infection cases, and 56,757deaths.
4 India 2,647,316 infection cases, and 51,045 deaths.
5 UK 318,484 infection cases, and 41,366 deaths.
6 Italy 253,915 infection cases, and 35,396 deaths.
7 France 218,536 infection cases, and 30,410 deaths.
8 Spain 358,843 infection cases, and 28,617 deaths.
9 Peru 535,946 infection cases, and 26,281 deaths.
WHO Director-General's opening remarks at the media briefing on COVID-19 - 13 August 2020
WHO, 13 August 2020
Good morning, good afternoon, good evening.
We’re half a year on from WHO sounding its highest alarm by declaring the COVID-19 outbreak a Public Health Emergency of International Concern.
At the time, on 30 January, there were just 100 cases outside of China and no deaths.
Since then there has been an exponential rise in cases and every country in the world has been impacted.
And with major disruptions to essential health services, the ripple effects of this pandemic are having a major impact politically, economically and in how people live their day-to-day lives.
Everyone is asking, so how do we go back to ‘normal’?
And today, I want to talk about not how we’re going to go back but how we’re going to go forward.
And that to move forward, the best bet is to do it together.
In early January, at the beginning of the outbreak, WHO activated our global technical networks to gather all available information about this virus.
Within the first two weeks of January, the viral genome of COVID-19 was mapped in China, shared globally and the first PCR test protocol was shared on the WHO website.
This enabled the first diagnostics to be developed, vaccine research to start and soon after millions of tests, PPE and supplies were shipped around the world.
In February, we held the WHO’s Research & Development Blueprint meeting where scientists and researchers from across the world came together to identify research priorities.
A roadmap was created for the development and fair distribution of diagnostics, therapeutics and vaccines.
Also, in February and March, numerous countries showed that it’s never too late to suppress COVID-19 using a comprehensive approach.
This includes active case finding and isolation, contact tracing and quarantine, adequate testing and appropriate clinical care.
With these tools it was clearly possible to break the chains of transmission by a combination of traditional public health techniques.
As the pandemic evolved, countries clearly needed to come together in an unprecedented way to develop new vaccines, diagnostics, and therapeutics – and to set the stage for ensuring that they reach all people, everywhere.
In April, WHO convened world leaders and launched the Access to COVID-19 Tools ACT-Accelerator.
In just three months, the accelerator has already shown results.
As of today:
Nine vaccine candidates are already in the COVAX portfolio and going through Phase 2 or 3 trials; and this portfolio – already the broadest in the world – is constantly expanding.
And through the COVAX Global Vaccines Facility, countries that represent nearly 70% of the global population have signed up or expressed an interest to be part of the new initiative.
On therapeutics, the first proven therapy for severe COVID-19, Dexamethasone, was announced in June with support from the therapeutic accelerator arm and is currently in scale-up.
On diagnostics, more than 50 tests are currently in evaluation, and new evidence has been generated around rapid antigen detection tests that could be game-changing.
The Act-Accelerator is the only global framework for ensuring the fair and equitable allocation of COVID-19 tools.
But it must be financed to be successful.
IMF estimates the pandemic costs the global economy $375 billion US dollars a month and predicts a cumulative loss to the global economy over two years of over $12 trillion US dollars.
The world has already spent trillions dealing with the short-term consequences of the pandemic.
G20 countries alone have mobilized more than $10 trillion US dollars in fiscal stimulus to treat and mitigate the consequences of the pandemic.
That is already more than three and a half times as much as the world spent in the entire response to the global financial crisis.
It’s easy to think of the ACT-Accelerator as a research and development effort; but in reality it’s the best economic stimulus the world can invest.
Funding the ACT-Accelerator will cost a tiny fraction in comparison to the alternative where economies retract further and require continued fiscal stimulus packages.
Before spending another $10 trillion US dollars on the consequences of the next wave, we estimate that the world will need to spend at least $100 billion US dollars on new tools, especially any new vaccines that are developed.
The first and most immediate need is $31.3 billion US dollars, for the ACT-Accelerator.
The ACT-Accelerator is the only up and running global initiative that brings together all the global R&D, manufacturing, regulatory, purchasing and procurement needed, for all the tools required, to end the pandemic.
Picking individual winners is an expensive, risky gamble.
The ACT-Accelerator enables governments to spread the risk and share the reward.
In particularly, the development of vaccines is long, complex, risky and expensive.
The vast majority of vaccines in early development fail.
The world needs multiple vaccine candidates of different types to maximize the chances of finding a winning solution.
When a successful new vaccine is found there will be greater demand than there is supply.
Excess demand and competition for supply is already creating vaccine nationalism and risk of price gouging.
This is the kind of market failure that only global solidarity, public sector investment and engagement can solve.
But the ACT-Accelerator funding gap can’t be covered by traditional development assistance alone.
The best solution for everyone is a blend of development assistance and additional financing from stimulus packages to fund this effort.
And this blend of financing is the best solution right now because it’s the fastest way to end the pandemic and ensure a swift global recovery.
We live in a globalised economy and countries are dependent on each other for goods and services, transportation and supply.
If we don't get rid of the virus everywhere, we can't rebuild economies anywhere.
And the real beauty of the ACT-Accelerator and its work is that stimulus investments and globally coordinated rollout of new vaccines, tests and therapeutics would have a major multiplier effect on our economies.
The sooner we stop the pandemic, the sooner we can ensure internationally inter-linked sectors like travel, trade and tourism can truly recover.
There is hope.
If we all deploy the tools currently at our disposal today and if we collectively invest in new tools through the Act-Accelerator, we have a route out of this pandemic.
Together! Together! Together with solidarity.
Over the past two years, working with the Government of the Democratic Republic of the Congo, communities, health workers and local and international partners, we collectively defeated one of the most difficult Ebola outbreaks the world has ever faced.
However, at the time of COVID-19, the outbreak in Equateur province is a worrying development.
So far there have been 86 Ebola cases across the province.
The country, government and partners face significant logistical challenges in being able to rapidly investigate and establish response capacities in extremely remote and difficult areas to access.
The geographic spread of the outbreak is vast, with cases in some areas separated by more than 250 kilometers and many areas are only accessible by helicopter or boat.
Right now, WHO has approximately 100 staff on the ground, working with the Ministry of Health, UN agencies, NGOs and communities.
We immediately released $2.5 million US dollars from the contingency fund for emergencies and our regional emergency response fund to support the immediate response.
To bring the outbreak under control and end it, WHO and partners require additional funding.
We’re currently working with surrounding provinces and neighboring countries to enhance preparedness as we did with the previous Ebola outbreak in Eastern DRC.
As we know from past experience, this is not just a matter for a countries health security, it is a matter of global health security.
Whether it’s COVID-19, Ebola or other high impact epidemics, we must be prepared, we need to be on high alert and we need to respond quickly.
And our best chance to be successful is always do it together.
I thank you.
South Africa steps up hygiene in health facilities to protect against COVID-19
WHO, 12 August 2020
Good hygiene practices such as hand hygiene, use of personal protective equipment and cleaning and disinfection of medical equipment and environment – just some of the elements of infection prevention and control (IPC) – are at the forefront of COVID-19 responses worldwide. They protect both patients and health workers from infection.
From the outset, the Government of South Africa prioritized scaling up of IPC; a vital component of quality care and a key element in achieving universal health coverage (UHC). The National Department of Health, among other measures, urgently approved the ‘National IPC Strategic Framework’ and a practical manual for its implementation, which was developed with support from WHO. The timing was crucial in order to support the national control and response to COVID-19.
In low- and middle-income countries, healthcare-associated infections are double those in high-income countries. Strong IPC measures will help save lives among the 58 million people living in South Africa, especially in vulnerable populations. They have a direct impact on preventing healthcare-associated infections and the spread of COVID-19, as well as in combatting current threats posed by epidemics such as Ebola and cholera, other pandemics like influenza, and antimicrobial resistance (AMR), which are increasingly major challenges to public health.
“I believe and trust that this strategic framework for IPC and the practical manual for its implementation will strengthen evidence-based infection practices at national, provincial, district and health facility levels towards combating threats posed by epidemics, pandemics and antimicrobial resistance,” said Dr Anban Pillay, Acting Director General, National Department of Health, South Africa.
This support was provided through the UHC Partnership as part of WHO’s overall COVID-19 response. The Partnership is funded by the European Union (EU), the Grand Duchy of Luxembourg, Irish Aid, the Government of Japan, the French Ministry for Europe and Foreign Affairs, the UK Department for International Development and Belgium.
***Share the link of this article with your facebook friends
Fair Use Notice
This site contains copyrighted material the
use of which has not always been specifically authorized by the copyright
owner. We are making such material available in our efforts to advance
understanding of environmental, political, human rights, economic,
democracy, scientific, and social justice issues, etc. We believe this
constitutes a 'fair use' of any such copyrighted material as provided for
in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C.
Section 107, the material on this site is
distributed without profit to those
who have expressed a prior interest in receiving the included information
for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml.
If you wish to use copyrighted material from this site for purposes of
your own that go beyond 'fair use', you must obtain permission from the
Opinions expressed in various sections are the sole responsibility of their authors and they may not represent Al-Jazeerah & ccun.org.
email@example.com & firstname.lastname@example.org